206 related articles for article (PubMed ID: 20979689)
1. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
2. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
4. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
7. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
8. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB; Legha SS; Gonzalez R; Anderson CM; Johnson MM; Liu P; Papadopoulos NE; Eton O; Plager C; Buzaid AC; Prieto VG; Hwu WJ; Frost AM; Alvarado G; Hwu P; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Benjamin RS; Bedikian AY
Melanoma Res; 2009 Feb; 19(1):42-9. PubMed ID: 19430405
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
11. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?
Sabel MS; Sondak VK
Drugs; 2003; 63(11):1053-8. PubMed ID: 12749732
[TBL] [Abstract][Full Text] [Related]
13. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
14. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
Di Trolio R; Simeone E; Di Lorenzo G; Grimaldi AM; Romano A; Ayala F; Caracò C; Mozzillo N; Ascierto PA
Anticancer Res; 2012 Sep; 32(9):3901-9. PubMed ID: 22993335
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Sondak VK; Flaherty LE
Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
[No Abstract] [Full Text] [Related]
17. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
18. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
[No Abstract] [Full Text] [Related]
19. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
